Actionable Tissue Intelligence
for Drug Development
Nucleai helps biopharma answer two critical questions: why does a therapy work, and which patients will benefit?
Our AI-driven, expert-led approach combines multimodal tissue analysis with clinical outcomes linkage and traceable outputs, turning complex tissue biology into actionable intelligence.
What Tissue Intelligence Means
Multimodal by Design
Integrate H&E, IHC, multiplex imaging, and spatial transcriptomics.
AI-Powered Tissue Analysis
Advanced models extract image features in greater depth to reveal spatial context.
Linked to Clinical Outcomes
Establish which features explain response, resistance, survival.
Traceable & Explainable
Trace every finding back to the tissue image it came from.
From First Signal to Clinical Trial Deployment
For discovery and translational research: from early signal and mechanistic understanding, to biomarker discovery and threshold-setting, to features tested and validated against clinical outcomes.
For patient selection in trials and companion diagnostic development: a validated spatial biomarker built into a deployable scoring algorithm under design controls, running inside the trial workflow your sites already use.
- Developing an antibody-drug conjugate?
Inside the Platform
Platform Overview
One platform to map tissue across imaging modalities, and link to outcomes.
Capabilities
From raw image to actionable intelligence, in one configurable pipeline.
Data and Modalities
A dedicated analytical approach for each data type, co-registered into one dataset per patient.
Trusted by Leading Biopharma and Research Partners
Data and Institutional Partners
Investors
Certified to Quality & IT Standards
